Cargando…
Complement Inhibition in ANCA-Associated Vasculitis
Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activati...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307875/ https://www.ncbi.nlm.nih.gov/pubmed/35880179 http://dx.doi.org/10.3389/fimmu.2022.888816 |
_version_ | 1784752858511441920 |
---|---|
author | Tesar, Vladimir Hruskova, Zdenka |
author_facet | Tesar, Vladimir Hruskova, Zdenka |
author_sort | Tesar, Vladimir |
collection | PubMed |
description | Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activation of alternative complement pathway plays an important role in the pathogenesis of AAV. Avacopan (C5a receptor inhibitor) was demonstrated to have at least similar efficacy and better safety (in terms of corticosteroid-related adverse events) compared with high-dose corticosteroids in the induction treatment of AAV. Other modes of the inhibition of alternative complement pathway are currently tested in AAV or could be considered on the basis of the experience in other glomerular diseases. |
format | Online Article Text |
id | pubmed-9307875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93078752022-07-24 Complement Inhibition in ANCA-Associated Vasculitis Tesar, Vladimir Hruskova, Zdenka Front Immunol Immunology Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activation of alternative complement pathway plays an important role in the pathogenesis of AAV. Avacopan (C5a receptor inhibitor) was demonstrated to have at least similar efficacy and better safety (in terms of corticosteroid-related adverse events) compared with high-dose corticosteroids in the induction treatment of AAV. Other modes of the inhibition of alternative complement pathway are currently tested in AAV or could be considered on the basis of the experience in other glomerular diseases. Frontiers Media S.A. 2022-07-08 /pmc/articles/PMC9307875/ /pubmed/35880179 http://dx.doi.org/10.3389/fimmu.2022.888816 Text en Copyright © 2022 Tesar and Hruskova https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tesar, Vladimir Hruskova, Zdenka Complement Inhibition in ANCA-Associated Vasculitis |
title | Complement Inhibition in ANCA-Associated Vasculitis |
title_full | Complement Inhibition in ANCA-Associated Vasculitis |
title_fullStr | Complement Inhibition in ANCA-Associated Vasculitis |
title_full_unstemmed | Complement Inhibition in ANCA-Associated Vasculitis |
title_short | Complement Inhibition in ANCA-Associated Vasculitis |
title_sort | complement inhibition in anca-associated vasculitis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307875/ https://www.ncbi.nlm.nih.gov/pubmed/35880179 http://dx.doi.org/10.3389/fimmu.2022.888816 |
work_keys_str_mv | AT tesarvladimir complementinhibitioninancaassociatedvasculitis AT hruskovazdenka complementinhibitioninancaassociatedvasculitis |